APOE ε4, Plasma p-tau217, and REM Sleep Disorder in Practice

A 54-year-old comes in holding a consumer genotyping report. APOE ε4/ε4 is flagged in red. She's cognitively intact and wants to know if this is a death sentence.

APOE ε4 is a variant of the APOE gene — the gene encoding the brain's main lipid transporter — that roughly triples lifetime Alzheimer's risk per copy. Two copies, like hers, raises population-level risk somewhere in the range of eight to twelve fold compared to the common ε3/ε3 genotype. But that is a relative risk on a population base rate. Most ε4/ε4 carriers do not develop dementia before their seventies, and some never do.

So what do I actually tell her?

You tell her the pathology of Alzheimer's starts roughly fifteen to twenty years before symptoms — that comes from autosomal dominant family cohorts and amyloid PET in cognitively normal people. Which means that her fifties are the window. The biology is already running. APOE ε4 doesn't set a date; it changes the slope.

What do I actually do for her? Because she's going to ask for a plan.

The most evidence-backed section of any dementia-prevention plan is vascular. Blood pressure control, especially in midlife — SPRINT MIND showed that intensive systolic targets reduced white matter lesion accrual and trended toward less cognitive impairment, though that trial wasn't powered for dementia as a primary endpoint. Aerobic exercise has randomized trial data supporting hippocampal volume and cognitive outcomes. Hearing loss treatment — the ACHIEVE trial showed benefit in a higher-risk subgroup. Sleep, metabolic health, social engagement — those have observational support, not clean randomized evidence.

What about the plasma p-tau217 result — that's a different situation. Cognitively intact, 61-year-old, result came back elevated. What am I looking at?

p-tau217 is a fragment of tau protein — tau is a structural protein inside neurons — phosphorylated at position 217, measurable in blood. An elevated result in a cognitively intact person means there is almost certainly amyloid accumulating in the brain. Multiple validation studies against amyloid PET show high concordance. This is not a screening test for the general population; it was validated in people with a clinical indication — family history, subjective cognitive concerns, APOE ε4 status.

Does a high result change what I prescribe?

Not pharmacologically, not yet. Lecanemab and donanemab are approved for mild cognitive impairment or mild dementia with confirmed amyloid — not cognitively intact individuals. Trials in the pre-symptomatic space are running, but there's no approved indication there. What the result changes is the urgency of the modifiable risk factor conversation and the follow-up interval.

Third scenario — a 58-year-old whose wife has moved to the spare room because he shouts and punches during dreams. I'm thinking REM sleep behavior disorder.

Correct. REM sleep behavior disorder — acting out vivid dreams because the normal muscle paralysis of REM sleep fails — is a prodromal synucleinopathy marker. Longitudinal data show that more than 80 percent of people with idiopathic REM sleep behavior disorder eventually convert to Parkinson's disease, Lewy body dementia, or multiple system atrophy, typically over a decade or more.

What do I do with him?

You confirm the diagnosis — ideally with a sleep study, because clinical history alone misses it in a third of cases. You look for other prodromal signs: anosmia, constipation, orthostatic hypotension. No neuroprotective therapy is approved or has clinical-endpoint evidence for this stage. Clonazepam or melatonin reduces injury risk during episodes — that's supportive, not disease-modifying. And you counsel him that this is a surveillance situation, not a diagnosis of Parkinson's yet.

So across all three cases — the APOE result, the high p-tau, the sleep disorder — the hardest part isn't the medicine.

The counseling is the hard part. These are real signals in people who feel well. The test didn't cause a disease; it revealed a trajectory. Your job is to translate that into things they can actually act on — not to send them home terrified of a number.

What's the single thing you'd want me to remember?

The window where risk-factor modification buys something is the forties, fifties, and sixties — not after the symptom appears. A memory clinic referral for someone already impaired is a late event. The visit that matters most for dementia is the routine one you're already having in midlife.